AFFY Affymax Inc.
- 1.46 P/E
- 107.12 P/S
- 0.87 P/B
- 0.082 EPS
- 0 / 0% Dividend
- 210,166.00 Avg. Vol.
- 37.50M Shares
- 4.5M Market Cap.
Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...
Argyll Free Press - Sep 28, 2014
Stockhouse - Sep 19, 2014
MarketWatch - Oct 1, 2014
Reuters Key Development - Jun 24, 2014
Reuters Key Development - Jun 13, 2014
Reuters Key Development - Jun 7, 2013
Reuters Key Development - Apr 26, 2013
Reuters Key Development - Apr 13, 2013
Reuters Key Development - Mar 25, 2013